PDX Portal

Model Details

Patient Information for Model: HCI-028

Model Contact

Model: HCI-028
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: HCI-028

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

There are no omics data for this model.

Drug Studies for Model: HCI-028

Treatment Response Across All Studies

CR <=-95% to -100% PR <-30% to >-95% SD >=-30% to +20% PD >=+20% NA

Drug Study: T104-T109

Study Metadata

Study ID: T104-T109
Study Type: Efficacy
Study Description:
Dosing Initiation Timepoint:
Number of Arms: 2
Mouse Strain:

PI: Alana Welm
Study Title: Birinapant Efficacy Study
Treatments: Birinapant
Study Duration:
Transplant Site
Transplant Material:

Study Design

Study Description	Arm Type	Treatment Arms	Number of Mice	Dose (mg/kg)	Concentration (mg/ml)	Vehicle	Route	Dosing Schedule
	Treatment	Birinapant		20
	Control	Vehicle

Treatment Results

Treatment Arm	Treatment Duration	Monitoring Method	Monitor Duration	Tumor volume over time (%)	Response Category
Birinapant			32	-94	PR
Vehicle			32	815	PD

Histology Information for Model: HCI-028

There are no histology images for this model.

Metastasis Information for Model: HCI-028

Patient

PDX

Abdomen

Adrenal gland

Bone

Bone (de novo)

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

LMD

Liver

Lung

Lymph node

Lymph nodes

Neck

None

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

medistinal and right hilar

Patient Treatment Information for Model: HCI-028

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response
10	Adriamycin/Cyclophosphamide, Paclitaxel	Neoadjuvant	26.41	26.58	62 days	Progressive disease
15	Paclitaxel	Neoadjuvant	26.58	26.75	62 days	Progressive disease
20	Radiation Therapy	Neoadjuvant	26.91	27.0	33 days	Progressive disease
25	Tamoxifen	Neoadjuvant	27.3	27.4	36 days	Progressive disease
30	Femera	Neoadjuvant	29.16	29.33	62 days	Progressive disease
35	Pertuzumab, Trastuzumab, Docetaxel	Neoadjuvant	29.33	29.83	183 days	Progressive disease
40	Zometa	Neoadjuvant	29.34	29.34	1 day	Progressive disease
45	Femera	Neoadjuvant	29.83	29.91	29 days	Progressive disease
50	Everolimus/Aromasin	Neoadjuvant	30.16	30.2	15 days	Progressive disease
55	Xeloda/Lapatinib	Neoadjuvant	30.25	30.3	18 days	Progressive disease
60	Taxotere, Pertuzumab/Trastuzumab	Neoadjuvant	30.33	30.41	29 days	Progressive disease
65	Kadcyla	Neoadjuvant	30.75	30.91	58 days	Progressive disease
70	Methotrexate change to IT topotecan	Neoadjuvant	30.91	31.08	62 days	Progressive disease
80	ThioTepa	Adjuvant	31.25	31.3	18 days	Progressive disease
85	IT liposomal cytarabine	Adjuvant	31.33	31.41	29 days	Progressive disease